Recent Company News

• 08:39 AM ET Oct 21, 2025
  

  Recent RWE Data show benefits of cell-based influenza vaccines relative to standard egg-based influenza vaccines (A$220.41, 0.00)

• 08:31 AM ET Oct 21, 2025
  

  Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines

• 05:11 PM ET Oct 08, 2025
  

  NICE recommends garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema

• 09:43 PM ET Sep 28, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 08:30 PM ET Sep 29, 2025
  

  Aurinia Pharmaceuticals responds to now retracted LinkedIn post referencing voclosporin by FDA official; stands behind the favorable benefit/risk profile of LUPKYNIS (voclosporin) ($11.06, 0.00)

• 06:09 PM ET Sep 29, 2025
  

  CSL CFO Joy Linton to step down, effective 7-Oct (A$199.00, 0.00)

• 12:50 PM ET Sep 26, 2025
  

  White House says the latest pharmaceutical tariffs do not apply to countries with negotiated trade deals -- wires

• 02:30 AM ET Sep 26, 2025
  

  CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

• 12:52 AM ET Sep 26, 2025
  

  StreetAccount Summary: Australia and New Zealand Stocks reaching new 52-week highs/lows (52 total)